⌕
Abbvie · ABBV · NYSE
Tenet 42 · Weak
Compare
$294.55−0.16%At closeTenet 42 · Weak
$294.55−0.48 (−0.16%)
At close: Nov 16, 2026, 4:00 PM ET· NYSE · USD
$294.51−0.04 (−0.01%)
After hours: Nov 16, 2026, 5:50 PM ET

Abbvie (ABBV) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● The Motley FoolNov 14, 2026 · 04:44 ET
Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy?

Pfizer offers one of the highest yields in healthcare. AbbVie is a Dividend King with solid growth prospects.…

● Defense WorldNov 14, 2026 · 04:42 ETEARNINGS EXPECTED BY FEB 2
AbbVie Inc. $ABBV Stock Sold by BCV Asset Management Inc.

BCV Asset Management Inc. trimmed its holdings in shares of AbbVie Inc. (NYSE: ABBV) by 2.2% during a recent quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SE…

● Zacks Investment ResearchNov 12, 2026 · 14:01 ETEARNINGS EXPECTED BY FEB 2
How Did AbbVie's Immunology Franchise Fare in Q3?

ABBV's immunology sales rose 16.6% in Q3, driven by Skyrizi and Rinvoq growth, prompting higher 2026 sales forecasts despite Humira's decline.…

● Zacks Investment ResearchNov 11, 2026 · 12:41 ET
ABBV Stock Rises More Than 4% in a Month: Time to Buy, Hold or Sell?

AbbVie's strong immunology and neuroscience growth offset Humira erosion and persistent aesthetics and oncology challenges.…

● Defense WorldNov 10, 2026 · 03:53 ETEARNINGS EXPECTED BY FEB 2
AbbVie Inc. $ABBV Stock Bought by AlphaCore Capital LLC

AlphaCore Capital LLC grew its stake in AbbVie Inc. (NYSE: ABBV) by 11.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor ow…

● Defense WorldNov 9, 2026 · 04:03 ETEARNINGS EXPECTED BY FEB 2
CenterBook Partners LP Purchases New Stake in AbbVie Inc. $ABBV

CenterBook Partners LP acquired a new stake in AbbVie Inc. (NYSE: ABBV) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 7,216 shares o…

● Zacks Investment ResearchNov 5, 2026 · 19:26 ET
2 Defensive Healthcare Stocks Hitting New 52-Week Highs: ABBV & LLY

As tech stocks retreat, AbbVie (ABBV) and Eli Lilly (LLY) are hitting fresh 52-week highs, offering investors defensive healthcare exposure with compelling growth potential.…

● Zacks Investment ResearchNov 4, 2026 · 10:01 ET
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.…

● ReutersNov 3, 2026 · 19:08 ET
AbbVie expands Oxford R&D facility as part of £120 million-plus investment

AbbVie expands Oxford R&D facility as part of £120 million-plus investment…

● 24/7 Wall StreetNov 3, 2026 · 11:03 ETEARNINGS EXPECTED BY FEB 2
AbbVie Hit a New High After Earnings. There's More Upside Left.

AbbVie just logged a 33% gain for the year and raised its guidance again, but the real question is whether Skyrizi and a newly closed pipeline deal can push shares even further past a valuation that already looks stretch…

● PRNewsWireNov 3, 2026 · 08:00 ET
Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026

– Nine abstracts will be presented, including new data from Phase 4 research examining aesthetic treatment following medical weight loss, with a focus on patient satisfaction and psychosocial outcomes – A digital image a…

● PRNewsWireOct 30, 2026 · 07:46 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 2
AbbVie Reports Third-Quarter 2026 Financial Results

Reports Third-Quarter Diluted EPS of $2.37 on a GAAP Basis, an Increase of Over 100.0 Percent; Adjusted Diluted EPS of $3.82, an Increase of Over 100.0 Percent; These Results Include an Unfavorable Impact of $0.11 Per Sh…

● PRNewsWireOct 27, 2026 · 08:00 ETCOMPANY'S OWN WORDS
AbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma

–  Etentamig is a second-generation BCMA-directed bispecific antibody T-cell engager with a clinical profile and dosing schedule that can potentially support treatment across a broad range of settings, including in commu…

● PRNewsWireOct 23, 2026 · 15:33 ET
U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease

Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector (OBI) device throughout the course of treatment In the pivotal Phase 3 AFF…

● PRNewsWireOct 22, 2026 · 09:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 2
AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa

In the Phase 3 INTREPID study, lutikizumab achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16 compared with placebo1 Lutikizumab met 8 ranked secondary endpoints, includin…

● PRNewsWireOct 21, 2026 · 08:00 ET
Allergan Aesthetics Deepens Science Behind Multimodal Approach at AMWC Dubai, Backed by Growing HArmonyCa™ Evidence

Allergan Aesthetics will present eight scientific posters featuring new and long-term evidence across HArmonyCa™, JUVÉDERM ® , SKINVIVE™ and BOTOX ® Cosmetic The latest HArmonyCa™ data reinforces its dual-action technolo…

Expected by Feb 2. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

Article counts from the last market-wide feed page, across every symbol we track and not just ABBV · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.